Page 14 - JCTR-11-4

Journal of Clinical and
Translational Research Hidden cancer after VTE

Overall mortality, n (%) Limited Extensive tests tests 11 7 (11.3) (7.1) 8 8 (4.1) (4.1)

Cancer‑related mortality, n (%) Limited Extensive tests tests 4 2 (4.1) (2.0) 5 2 (2.5) (1.0)

Cancer detection during follow‑up, n (%) Limited Extensive tests tests 2 2 (2.0) (2.0) 9 1 (4.7) (0.5)

Cancer detection at initial screening, n (%) Limited Extensive tests tests 8 10 (8.2) (10.2) 4 11 (2.0) (5.6)

Follow ‑up 24 months 24 months

Limited tests Tests at the physician’s discretion Medical history, physical examination, usual laboratory tests, and basic radiographs Abbreviations: α‐FP: Alpha‐fetoprotein; CEA: Carcinoembryonic antigen; CT: Computed tomography; NA: Not available; PET/CT: Positron emission tomography/computed tomography;

Intervention Extensive tests Thoracic, abdominal, and pelvic CT-scan in combination with fecal occult blood test Limited tests plus PET/CT

Mean age/female, n Limited Extensive tests tests 69.0/50 69.3/44 62/95 64/92

Limited tests 97 197
Sample size Extensive tests 98 197

Study period January 2006 to May 2008 March 2009 to August 2012
Table 1. (Continued) Country Author, year Italy Prandoni et al., 2016 18 France Robin et al., 2016 (MVTEP study) 19 PSA: Prostate‐specific antigen.

Volume 11 Issue 4 (2025) 8 doi: 10.36922/jctr.24.00069